In a groundbreaking development, the Union Minister of State for Science & Technology recently unveiled India's first native CRISPR-based gene therapy known as BIRSA 101. This revolutionary treatment is designed to combat Sickle Cell Disease (SCD), marking a significant advancement in genetic therapies within the country.
BIRSA 101 stands as India's inaugural CRISPR-based gene therapy specifically tailored for Sickle Cell Disease. It proudly bears the name of the legendary tribal leader, Birsa Munda, symbolizing a tribute to his legacy. The therapy is an innovative creation of the CSIR-Institute of Genomics and Integrative Biology (IGIB).
BIRSA 101 effectively addresses the root cause of Sickle Cell Disease by accurately correcting the genetic mutations. Administered as a one-time infusion, the therapy facilitates the production of normal red blood cells, replacing the defective sickle-shaped cells.
Sickle Cell Disease is a hereditary disorder characterized by the abnormal shape and rigidity of red blood cells, impairing their ability to carry oxygen efficiently. This condition can lead to blockages in blood vessels, causing severe pain episodes, chronic pain, organ damage, anemia, infections, and even strokes. Individuals can be carriers without showing symptoms, but the risk of a child inheriting the disease increases if both parents are carriers or if one parent has the disease while the other is a carrier.
Learn more about the revolutionary BIRSA 101 and its implications on Sickle Cell Disease by visiting this link.
Kutos : AI Assistant!
